AstraZeneca Ultomiris Phase 3 miss in adult HSCT-TMA boosts OMER

AstraZeneca Ultomiris Phase 3 miss in adult HSCT-TMA boosts OMER 16%

• AZN announced today that Ultomiris missed primary endpoint of event-free survival at 26 weeks in ALXN1210-TMA-313 trial (adults/adolescents 12+).
• Only trend toward benefit observed; AZN proceeding with filings but data viewed as weak.
• Omeros' YARTEMLEA (narsoplimab) remains sole FDA-approved therapy for TA-TMA with differentiated MASP-2 mechanism.
• YARTEMLEA offers better safety profile (avoids infection risks of C5 inhibitors like Ultomiris).
• Investor chatter on X and biotech forums highlights strengthened competitive position for OMER.
• Builds on YARTEMLEA's U.S. commercial launch and July J-code implementation.

https://finviz.com/stock?t=OMER&p=d